Is VolitionRX Ltd. overvalued or undervalued?

As of 14 November 2024, the valuation grade for VolitionRX Ltd. has moved from does not qualify to risky, indicating a significant deterioration in its investment profile. The company appears to be overvalued, given its negative valuation ratios, including a Price to Book Value of -2.06 and an EV to EBITDA of -2.67, which suggest that the market is pricing the stock unfavorably compared to its fundamental value. Additionally, the EV to Sales ratio stands at 46.73, further highlighting the company's overvaluation relative to its revenue generation.
In comparison to its peers, VolitionRX Ltd. has a less favorable EV to EBITDA ratio than Perspective Therapeutics, Inc. at -0.7951 and Prenetics Global Ltd. at -1.5438, both of which also fall into the risky category. Notably, VolitionRX has underperformed against the S&P 500, with a 3-year return of -62.40% compared to the index's 70.41%, reinforcing the notion that the stock is struggling in the current market environment.